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Identity 
Other names: GD; GdA; GdF; GdS; MGC138509; 
MGC142288; PAEG; PEP; PP14 
HGNC (Hugo): PAEP 
Location: 9q34.3 
Local order: Several other lipocalin genes have been 
mapped on the same chromosomal region. From 
centromere to telomere (GeneLoc database): lipocalin 1 
(tear prealbumin, LCN1) - ENSG00000221613 - 
odorant binding protein 2A (OBP2A) - progestagen-
associated endometrial protein (PAEP) - 
ENSG00000237339 - LOC138159 - 
ENSG00000236543 - glycosyltransferase 6 domain 
containing 1 (GLT6D1) - lipocalin 9 (LCN9). 
DNA/RNA 
Note 
Many other lipocalin genes have similar exon/intron 
organization. 
Description 
Maps to chromosome 9: 138453602-138458801 on 
forward (plus) strand (5200 bases). Gene consists of 7 
exons. Promoter region contains, by sequence 
similarity, 2 forward and two reverse Sp1-like binding 
sites, four putative glucocorticoid/progesterone 
response elements (PREs), cAMP responsive element 
(CRE) and activator protein-1 (AP-1) element. 
Transcription 
PAEP mRNA (NM_001018049) has 857 bp. Several 
alternatively spliced mRNA forms have been 
described, but for most of these evidence for the 
corresponding protein lacks. Alternative Splicing and 






Some of the localization studies have employed 
antibodies, the specificity of which is questionable. 
Some of the biological studies have utilized short 
peptides derived from PAEP sequence. It is unclear 
whether such peptides are present in vivo. 
Glycosylation plays an important part in 
modulating/dictating the activity of PAEP. In the 
literature, PAEP is widely referred to as PP14 and 
glycodelin. 
Description 
PAEP (180 amino acids, of which 18 corresponds to 
signal sequence) is a 28 kDa secreted glycoprotein, 
belonging to the kernel lipocalin family. Most family 
members share three conserved sequence motifs. 
Although sequence similarity between the family 
members is low, their three dimensional structures are 
similar.  
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Chromosomal location and gene structure of PAEP. Promoter region shows some of the potential regulatory elements. After translation- 
initiating codon (ATG) exons of the major transcript are shown in black. Some splicing variants contain also parts outside of these exons. 
PRE: glucocorticoid/progesterone response element; CRE: cAMP responsive element; Sp1: Sp1 transcription factor binding site; AP-1: 
activator protein-1 element. 
 
Lipocalins are small extracellular proteins, many of 
which bind small hydrophobic molecules, such as 
retinol and steroids. There is no evidence that PAEP 
exhibits similar binding properties. PAEP is a 
glycoprotein with three potential glycosylation sites. 
Two of them are glycosylated. Many differentially 
glycosylated forms have been characterized in these 
sites. Glycosylation modulates/dictates the biological 
activity of PAEP. Some of the alternatively spliced 
mRNAs lack the sequences encoding glycosylation 
sites and/or the lipocalin signature sequence. 
Expression 
The expression of PAEP is highly regulated in a 
spatiotemporal fashion. In the female, PAEP is mainly 
expressed in secretory/decidualized endometrial glands 
after progesterone exposure. In secretory endometrium, 
expression becomes detectable four days after 
ovulation and reaches maximum at the end of the 
menstrual cycle unless pregnancy ensues. PAEP is one 
of the major proteins in endometrial secretions. In the 
male, the highest expression has been reported in 
seminal vesicles. PAEP is also expressed in other 
epithelial cells of reproductive tissues, such as fallopian 
tubes, ovary and the breast. In addition, other secretory 
epithelia, such as eccrine sweat glands and the 
bronchus epithelium express PAEP. It is also expressed 
in differentiated areas of breast cancer, ovarian tumors, 
endometrial adenocarcinoma, and synovial sarcoma. In 
addition to epithelial tissues, PAEP has been found in 
megakaryocytes and erythroid precursor cells. 
Experimental evidence suggests that PAEP expression 
is regulated by progesterone/progestins, relaxin, and 
histone deacetylase inhibitors. 
Localisation 
PAEP is mostly found in exocrine epithelial cells, from 
which it is secreted into the gland lumen. In breast 
cancer, PAEP has been found also in paranuclear 
vacuoles of lobular carcinoma cells. 
Function 
PAEP/PP14/glycodelin regulates the functions of 
spermatozoa during fertilization in a glycosylation 
dependent manner.  
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Swiss model-deduced tertiary structure of the PAEP monomer. The S-S bridge is shown as cylinder and side chain nitrogen atoms of 
asparagines of potential glycosylation sites are shown as balls. Below are representative examples of the major complex-type glycans 
present at the N-glycosylation sites Asn 28 and Asn 63 of amniotic fluid glycodelin-isoform (glycodelin-A) and seminal plasma glycodelin-
isoform (glycodelin-S). Some of the characteristic epitopes are marked by broken line. 
 
The various glycoforms of PAEP have different, 
sometimes even opposite, biological actions at different 
phases of the fertilization process. Seminal fluid 
glycodelin-S binds to the sperm head and inhibits 
premature capacitation. In the female reproductive 
tract, spermatozoa come into contact with various 
PAEP glycoforms, that modulate sperm function, e.g., 
by preventing premature, progesterone-induced 
acrosome reaction (glycodelin-F). Glycodelin-A 
inhibits binding of spermatozoa to the zona pellucida, 
whereas another glycoform (glycodelin-C) stimulates 
the same. All these actions are glycosylation-
dependent. 
PAEP also regulates immune cell functions, which too 
are, at least in part, regulated by glycosylation. 
Different PAEP glycoforms contain diverse bi-, tri-, 
and tetra-antennary complex-type glycans with varying 
levels of fucose and sialic acid substitution. 
Glycodelin-A and -F are the most heavily sialylated 
and inhibit cell proliferation, induce cell death, and 
suppress interleukin-2 secretion of Jurkat cells and 
peripheral blood mononuclear cells. No such 
immunosuppressive effect has been observed for 
glycodelin-C and -S carrying less or no sialic acids, or 
for desialylated glycodelin-A and -F. By its 
immunosuppressive properties one of the PAEP 
glycoforms (glycodelin-A) may contribute to 
immunotolerance at the fetomaternal interface and 
prevent rejection of the fetal semi-allograft. 
In early pregnancy, glycodelin-A restrains 
inappropriate invasion of extravillous cytotrophoblasts 
by suppressing activity of some key metalloproteinases. 
In breast and endometrial cancer cell lines, PAEP has 
been found to revert the malignant phenotype in vitro 
by inducing morphological differentiation and specific 
gene expression changes. In a preclinical mouse model, 
transgenic PAEP expression in breast cancer cells has 
reduced tumor growth. 
Homology 
Most lipocalins do not share high sequence similarity, 
but they are likely to be homologous. 
Functional PAEP gene has been found in higher 
primates. Beta-lactoglobulins represent orthologs of 
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PAEP, but they are likely to be functionally different 
from human PAEP, not least because of their 
differences in glycosylation. No convincing evidence 
of a PAEP ortholog in mouse or rat has been reported. 
Mutations 
Note 
NCBI SNP database reports 128 PAEP SNPs (Homo 
sapiens, 13 September 2010). Also HinfI restriction 
enzyme polymorphism has been reported in Finnish 
population with 5% frequency for allele A1 and 95% 
frequency for allele A2. No disease associations for 




PAEP is expressed in both normal and malignant 
ovarian tissue. PAEP has been localized to the 
cytoplasm of tumor cells and its staining is more 
frequent in well-differentiated than in poorly 
differentiated carcinomas. Nuclear progesterone 
receptors (PRA and PRB) are often coexpressed with 
cytoplasmic PAEP. 
Disease 
In 2002, ovarian cancer was the 6th most common 
cancer in women, and 7th most common cause of 
cancer death. Most malignant neoplasms of the ovary 
originate from the coelomic epithelium. 
Prognosis 
In ovarian serous carcinoma, PAEP expression is 
associated with a more favorable prognosis, even in 
patients with the same tumor grade and clinical stage. 
Breast cancer 
Note 
In breast cancer tissue, PAEP staining has been found 
in both estrogen and progesterone receptor negative 
and positive cancers. PAEP is also present in normal 
breast tissue. Transfection of PAEP in MCF-7 breast 
cancer cells reverted the malignant phenotype of the 
cells by inducing morphological differentiation and 
specific gene expression changes. Furthermore, these 
cells showed reduced tumor growth in a preclinical 
xenograft tumor mouse model. 
Disease 
Breast cancer is the most common cancer among 
women worldwide. Although the prognosis has 
improved following improved diagnosis and therapies, 
breast cancer remains an important cause of death 
among women. Most of the neoplasms of the breast 
originate from the ductal epithelium, while a minority 
originates from the lobular epithelium. Family history 
of breast cancer is associated with a 2-3-fold higher 
risk of the disease. 
 
Prognosis 
In sporadic breast cancer, PAEP is associated with low 
proliferation rate and well-differentiated tumors, 
whereas in familial "non BRCA1/BRCA2" patients, 
PAEP expression is associated with a less favorable 
phenotype and increased risk of metastases. 
Reproductive failure 
Note 
During the period of endometrial receptivity for 
implantation, reduced PAEP secretion/serum levels 
have been observed in reproductive failure, e.g. in 
unexplained infertility or recurrent early pregnancy 
loss. 
Disease 
Unexplained infertility or recurrent miscarriage may 
result from inadequate implantation and/or 
placentation. 
Polycystic ovary syndrome (PCOS) 
Note 
Pregnant women with PCOS who subsequently 
miscarry show subnormal rise of PAEP serum 
concentration during the first trimester. 
Disease 
PCOS is a common endocrine disorder in fertile-aged 
women. It is associated with ovulatory disturbance, 
insulin resistance and androgen excess, and is a 
frequent cause of menstrual disorders and infertility in 
women. 
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